Last reviewed · How we verify
KIN-2787
At a glance
| Generic name | KIN-2787 |
|---|---|
| Also known as | exarafenib |
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KIN-2787 CI brief — competitive landscape report
- KIN-2787 updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI